#United States #FSHD Society #SOLVE FSHD #FSHD CTRN #Randolph, Massachusetts

Launch of a Collaborative Initiative to Improve FSHD Clinical Trials

In a significant development, the FSHD Society, alongside SOLVE FSHD and the FSHD Clinical Trial Research Network (FSHD CTRN), has announced the establishment of the FSHD Industry Collaborative. This innovative, multi-stakeholder initiative is set to transform the landscape of clinical trials for facioscapulohumeral muscular dystrophy (FSHD), bringing together a wealth of expertise from various fields.

A Unique Approach to Clinical Trials

The FSHD Industry Collaborative is unlike traditional single-sponsor data analyses. It operates under a unique pre-competitive framework designed to facilitate a broader, collective examination of data from multiple sources. By harnessing the collective knowledge and resources of industry experts in drug development and academic researchers, the Collaborative aims to improve patient selection, refine clinical measurements, and enhance regulatory narratives for FSHD programs.

Eva Chin, Executive Director of SOLVE FSHD, emphasized the significance of the initiative, stating, "We are excited to provide foundational funding support for this collaborative effort that seeks to advance biomarker development for FSHD." This effort will amalgamate natural history data and existing clinical trial information to create tools and infrastructure crucial for accelerating drug development and benefiting the FSHD community.

A Focus on Data-Driven Insights

The core activities of the Collaborative include:

• - Analysis of Clinical Data: New evaluations of donated clinical trial data and natural history datasets will be conducted to assess endpoint performance and variability drivers.
• - Biomarker Development: Developing and validating FSHD biomarker assays utilizing patient samples will be crucial, as these will be linked to imaging and functional outcomes data.

This systematic approach is expected to uncover new insights that could reduce risks in clinical development while addressing unmet needs in FSHD treatments.

Partnering for Progress

The FSHD CTRN plays an instrumental role in this ambitious project by providing extensive, longitudinal patient data from a network of over 30 academic centers across 10 countries. This collaboration also enjoys the support of biopharma giants like Sanofi and Fulcrum Therapeutics, the latter of which has generously shared clinical data from its previous trials, reinforcing the commitment to collective progress in treating FSHD.

Scholar Rock, a biopharmaceutical company known for developing therapies for neuromuscular diseases, is among the founding sponsors, with more drug developers in the pipeline to join. The Global FSHD Innovation Hub will oversee strategic management and provide advisory services necessary for conducting this collaboration.

Building on FDA Engagements

The project is designed to build on previous engagements with the U.S. Food and Drug Administration (FDA), which began with an Industry Collaborative Workshop in 2019. This workshop identified barriers to therapeutic development and fed into a series of events aimed at capturing real patient experiences and discussing critical unmet needs.

As stated by Dr. Lucienne Ronco, CSO of the FSHD Society, "Aligning patient experiences, scientific rigor, and regulatory expectations is essential for progress in FSHD." This initiative represents a logical continuation from earlier FDA discussions to data-driven executions of vital projects.

Invitation to Collaborate

The Collaborative is in its founding phase and actively seeks additional pharmaceutical and biotech companies, technology partners, and funders to join. Community contributions and philanthropic donations will be essential in furthering this critical work and generating insights that can significantly influence the FSHD ecosystem.

Amanda Rickard, Managing Director of the Global FSHD Innovation Hub, highlighted, "Access to high-quality clinical trial and natural history data is critical for improving trial designs for rare diseases. This research collaboration sets a rigorous framework for generating insights that individual FSHD programs cannot achieve alone."

With the establishment of the FSHD Industry Collaborative, there is renewed hope for advancing the understanding and treatment of FSHD, ultimately leading to better outcomes for patients living with this condition.